MENU CLOSE
About Us

Who We Are

Our Social Responsibility

Events

Exhibitions

Activeties

Members

Hospitals

Individuals

Companies

Member Benefits

 
Bio-medical projectsi

State Key Laboratory of Biotherapy

Cooperation

Achievement Exhibition

Scimea Journals

Signal Transduction and Targeted Therapy

News

News Information

 
Home   >  News
18 May 2020
44
Japan Kobe Translational Research Center for Medical Innovation (TRI) China Headquarters Officially Unveiled
SCIMEA

On May 18, the opening ceremony of the China Headquarters of Japan Kobe Translational Research Center for Medical Innovation (TRI) marked the official settlement and operation of major industrial projects in the Tianfu New Area which seizes opportunities for Sino-Japan cooperation. The inauguration ceremony was connected with TRI Japan headquarters through video. Masanori Fukushima, director of TRI and professor of Kyoto University, and Hideki Doi, president of Advanced Innovation Development Co.,Ltd.(AID) Co., Ltd. joined the video interact and delivered speeches. Liu Miaomiao, representative of TRI China and chairman of Snit Biotechnology Co., Ltd., emceed over the inaugural ceremony. Li Ang, member of the Party Working Committee of Chengdu Tianfu New Area, deputy director of the Management Committee, and secretary of the Party Working Committee of the Tianfu Headquarters Business District, attended the ceremony and delivered a speech.

Japan Kobe Translational Research Center for Medical Innovation (TRI) is the first data center and analysis center dedicated to clinical trials in Japan. 228 senior researchers of various types, including four Nobel Prize winners in physiology or medicine, Tasuku Honjo, Satoshi omura, Shinya Yamanaka, and Yoshinori Ohsumi, are devoted to providing clinical research services from research planning to data analysis and medical technology innovations for clinical research, with 126 products marketed and more than 400 product patents in clinical stage in Japan.

TRI China Headquarters is located in the Tianfu Headquarters Business District of Tianfu New Area. It mainly conducts basic, clinical and regenerative medicine R&D, promotes the marketing of patented Japanese new products in China and the achievement transformation of new drugs under study. It has also set up a platform for the medical summit between China and Japan, conducts clinical trials, and effectively promotes communication between Chinese and Japanese pharmaceutical companies.

In July 2019, Tianfu New Area contacted TRI for the first time to discuss possible investment and cooperation of TRI China headquarters;

In August, TRI China Headquarters project company-Snit Biotechnology Co., Ltd., was registered in Tianfu New Area;

In September, Tianfu New Area and TRI Japan formally reached a project investment and cooperation agreement;

In November, TRI Japan and Sichuan International Medical Exchange & Promotion Association jointly held the "2019 China-Japan Advanced Medical and New Drug R&D Summit Forum and Achievement Transformation Conference" in Chengdu, which attracted hundreds of leading pharmaceutical companies and top investment institutions from China and Japan. Academician Wang Fusheng from Chinese Academy of Sciences, Academician Wei Yuquan from Chinese Academy of Sciences, and Academician Tanaka Koyichi from the Japanese Academy of Sciences attended the conference. It contributed to the display and transformation of more than 1,000 leading-edge biomedical achievements in China including those developed under the guide of Academician Tasuku Honjo, Japan Nobel Prize winner, which fully demonstrated the project's international influence and industrial driving force.


The operation of TRI China Headquarters is of great significance for improving the biomedical R&D and internationalization, and for promoting the open cooperation between China and Japan in medicine and health in Tianfu New Area and even in the whole Chengdu area. As major medical and health projects such as TRI successively settle in, Tianfu New Area will gradually become the new growth pole of medical and health industry in Chengdu, help Chengdu accelerate its integration into the high-end global industrial chain, and the innovation and value chain cores, and build an internationally competitive medical and health industry ecosphere. At the same time, based on the TRI project, Tianfu New Area is committed to creating a new model of complementary cooperation in medicine and health between China and Japan, serving the overall national opening up, helping the improvement of Sino-Japanese relations, leading the comprehensive opening up of China and Japan, and promoting China-Japan local cooperation to a new stage.

 

 


Convey Benevolence and Solve Problems ▕ SCIMEA MDT Committee – Grassroots Academic Promotion
MedComm | Neurologic manifestations of nonhospitalized patients with COVID‐19 in Wuhan, China
Internal Training | Expense Payment and Financial Reimbursement Measures
Interview | Lai Xintian: Strengths of New Drug R&D in Sichuan, AI Proven Helpful for Efficiency Improvement
Member Unit Updates| CAS Academician Zhao Yuliang's first academician workstation in China successfully settled in the Affiliated Hospital of North Sichuan Medical College
Latest Events Journals News Members About Us Home
Contact Us

Address: No. 1103-1105, Building 6, S2, Global Center, High-tech Zone, Chengdu

Email: scimea@163.com 

Tel: (0086-)028-63859818   

Fax: (0086-)028-63859818   

Contact: (0086-)19113901604 (wechat:19113901604)


Follow Us
Copyright © 2009-2019 SCIMEA. All rights reserved 蜀ICP备19011649号-1